Physician profile
Nancy Rizza
NPI 1609362847
$7,010.21
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,316 · 2022: $3,885 · 2023: $658 · 2024: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.08 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,379.97 | 2021-2023 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $1,225.12 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $689.16 | 2021-2023 | Saphnelo |
| Ucb, INC. | $634.98 | 2021-2023 | Cimzia |
| Janssen Biotech, INC. | $592.33 | 2021-2023 | Tremfya, Simponi, Remicade |
| Mallinckrodt Hospital Products INC. | $420.73 | 2021-2023 | Acthar |
| Pfizer INC. | $338.54 | 2021-2023 | |
| Horizon Therapeutics Plc | $303.48 | 2022-2023 | |
| Glaxosmithkline, LLC. | $238.48 | 2021-2022 | |
| Lilly USA, LLC | $219.35 | 2021-2023 | Taltz |
| Organon LLC | $165.24 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.98 | 2021-2023 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $111.46 | 2022 | |
| Acadia Pharmaceuticals INC | $110.21 | 2024 | Nuplazid |
| Sobi, INC | $77.10 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $76.49 | 2021-2023 | Actemra |
| Novartis Pharmaceuticals Corporation | $46.43 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.45 | 2021-2022 | |
| Radius Health, INC. | $41.07 | 2022-2023 | Tymlos |
| Neurocrine Biosciences, INC. | $40.71 | 2024 | Ingrezza |
| Actelion Pharmaceuticals US, INC. | $33.55 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $32.07 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $25.14 | 2023 | Rexulti |
| Kiniksa Pharmaceuticals, LTD. | $21.29 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Rizza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.